FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895816735> ?p ?o ?g. }

• W2895816735 abstract "Purpose In a previous retrospective audit from our institution, access to human epidermal growth factor receptor 2 (HER2) –targeted therapy (H2T) in patients registered and treated in 2008 was reported, wherein only 38 (8.61%) of 441 patients received some form of H2T. Three developments occurred in subsequent years that potentially affected access to H2T at our institution—that is, a patient access program supported by the innovator pharmaceutical company, a generous philanthropic donor, and the use of biosimilars. Methods To evaluate the cumulative impact of these developments on access to trastuzumab, we reviewed access to H2T in a recent cohort of patients with breast cancer registered in at our institution. Results In 2016, 4,717 new patients with breast cancer were registered at our institution. Among these patients, HER2 3+ expression by immunohistochemistry or fluorescent in situ hybridization (FISH) was reported in 828 patients (22.77%). Assuming the same 33.22% amplification rate in the 343 patients who did not undergo FISH testing, there were potentially 114 more patients with HER2-amplified tumors. Thus, the final number of HER2-overexpressing/-amplified tumors is estimated to be 942 in 2016 (729 HER2 immunohistochemistry 3+, 99 known FISH amplified, and 114 estimated FISH amplified). Of these 942 patients, 13 were not deemed suitable for H2T and 94 did not follow-up for additional treatment at our institution. The remaining 835 patients were eligible to receive H2T and were analyzed for access to this treatment. Overall, 444 (53.2%) of these 835 patients received trastuzumab for durations that ranged from 12 weeks to 12 months in the (neo)adjuvant setting or other durations in the metastatic setting. This is in contrast to the previously reported 8.61% use of H2T in the cohort of patients registered in 2008. Conclusion We suggest that other institutions, especially public hospitals that treat underprivileged patients, make concerted efforts to increase access to potentially curative treatments, such as trastuzumab, using targeted programs and philanthropic support, and consider using a shorter duration of 12 weeks of trastuzumab to improve patient outcomes. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . No COIs from the authors." @default.
• W2895816735 created "2018-10-26" @default.
• W2895816735 creator A5013908300 @default.
• W2895816735 creator A5022310549 @default.
• W2895816735 creator A5048611916 @default.
• W2895816735 creator A5050720436 @default.
• W2895816735 creator A5066582496 @default.
• W2895816735 creator A5074723074 @default.
• W2895816735 creator A5076171969 @default.
• W2895816735 date "2018-10-01" @default.
• W2895816735 modified "2023-10-17" @default.
• W2895816735 title "Access to Human Epidermal Growth Factor Receptor 2–Targeted Therapy at a Tertiary Care Center in India: An Evolution" @default.
• W2895816735 doi "https://doi.org/10.1200/jgo.18.10310" @default.
• W2895816735 hasPublicationYear "2018" @default.
• W2895816735 type Work @default.
• W2895816735 sameAs 2895816735 @default.
• W2895816735 citedByCount "1" @default.
• W2895816735 countsByYear W28958167352019 @default.
• W2895816735 crossrefType "journal-article" @default.
• W2895816735 hasAuthorship W2895816735A5013908300 @default.
• W2895816735 hasAuthorship W2895816735A5022310549 @default.
• W2895816735 hasAuthorship W2895816735A5048611916 @default.
• W2895816735 hasAuthorship W2895816735A5050720436 @default.
• W2895816735 hasAuthorship W2895816735A5066582496 @default.
• W2895816735 hasAuthorship W2895816735A5074723074 @default.
• W2895816735 hasAuthorship W2895816735A5076171969 @default.
• W2895816735 hasBestOaLocation W28958167351 @default.
• W2895816735 hasConcept C121608353 @default.
• W2895816735 hasConcept C126322002 @default.
• W2895816735 hasConcept C143998085 @default.
• W2895816735 hasConcept C2775832928 @default.
• W2895816735 hasConcept C2779786085 @default.
• W2895816735 hasConcept C2991842025 @default.
• W2895816735 hasConcept C530470458 @default.
• W2895816735 hasConcept C71924100 @default.
• W2895816735 hasConcept C72563966 @default.
• W2895816735 hasConceptScore W2895816735C121608353 @default.
• W2895816735 hasConceptScore W2895816735C126322002 @default.
• W2895816735 hasConceptScore W2895816735C143998085 @default.
• W2895816735 hasConceptScore W2895816735C2775832928 @default.
• W2895816735 hasConceptScore W2895816735C2779786085 @default.
• W2895816735 hasConceptScore W2895816735C2991842025 @default.
• W2895816735 hasConceptScore W2895816735C530470458 @default.
• W2895816735 hasConceptScore W2895816735C71924100 @default.
• W2895816735 hasConceptScore W2895816735C72563966 @default.
• W2895816735 hasLocation W28958167351 @default.
• W2895816735 hasOpenAccess W2895816735 @default.
• W2895816735 hasPrimaryLocation W28958167351 @default.
• W2895816735 hasRelatedWork W1986373442 @default.
• W2895816735 hasRelatedWork W2067395077 @default.
• W2895816735 hasRelatedWork W2073796386 @default.
• W2895816735 hasRelatedWork W2214014382 @default.
• W2895816735 hasRelatedWork W2371996213 @default.
• W2895816735 hasRelatedWork W2464411047 @default.
• W2895816735 hasRelatedWork W2895816735 @default.
• W2895816735 hasRelatedWork W2944795438 @default.
• W2895816735 hasRelatedWork W2961448522 @default.
• W2895816735 hasRelatedWork W4226292667 @default.
• W2895816735 isParatext "false" @default.
• W2895816735 isRetracted "false" @default.
• W2895816735 magId "2895816735" @default.
• W2895816735 workType "article" @default.